Loading…
Loading…
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
NEW YORK, July 16, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Travere Therapeutics, Inc. (NASDAQ: TVTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on July 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 41,600 shares of its common stock to six new employees, consisting of inducement stock options to purchase an aggregate of 18,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 23,600 shares of its common stock. These inducement s.
HONG KONG, July 8, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaborat
Travere Therapeutics has transitioned into a rare disease commercial platform, driven by FILSPARI's strong growth in IgAN and recent FSGS approval. TVTX's premium valuation is justified by rapid revenue expansion, significant operating leverage, and strategic pipeline moves like the civorebrutinib acquisition. FILSPARI's unique positioning and first-mover advantage in FSGS, alongside a simplified REMS, support continued market penetration despite a competitive IgAN landscape.
SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company's chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the Company's executive leadership team, will expand her responsibilities to include the Company's research organization and be named executive vice president, head of research and development and CMO.
SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on June 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 32,000 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as i.
Travere Therapeutics, Inc. (TVTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for TVTX and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.